CA2562859A1 - Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug - Google Patents
Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug Download PDFInfo
- Publication number
- CA2562859A1 CA2562859A1 CA002562859A CA2562859A CA2562859A1 CA 2562859 A1 CA2562859 A1 CA 2562859A1 CA 002562859 A CA002562859 A CA 002562859A CA 2562859 A CA2562859 A CA 2562859A CA 2562859 A1 CA2562859 A1 CA 2562859A1
- Authority
- CA
- Canada
- Prior art keywords
- denotes
- denotes hydrogen
- fluorine
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
The invention relates to enantiomerically pure compound of formula 1 (see formula 1) wherein R1 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
R2 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
R3 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen, OH, -O-C1-C4-alkylene-COOH or -O-C1-C4-alkylene-COO-C1-C4-alkyl;
R4 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen; and X denotes an anion with a single negative charge, optionally in the form of a tautomer, mixture of tautomers, hydrate or solvate thereof.
A method for producing said compounds and the use thereof in the form of a drug, in particular as a drug for treating respiratory tract diseases are also disclosed. The synthesis of the compounds is carried out by means of a chiral epoxide.
R2 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
R3 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen, OH, -O-C1-C4-alkylene-COOH or -O-C1-C4-alkylene-COO-C1-C4-alkyl;
R4 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen; and X denotes an anion with a single negative charge, optionally in the form of a tautomer, mixture of tautomers, hydrate or solvate thereof.
A method for producing said compounds and the use thereof in the form of a drug, in particular as a drug for treating respiratory tract diseases are also disclosed. The synthesis of the compounds is carried out by means of a chiral epoxide.
Claims (15)
1) Enantiomerically pure compounds of general formula 1 wherein R1 denotes hydrogen, C1 -C4-alkyl, C1-C4-alkoxy or halogen;
R2 denotes hydrogen, C1-C4-alkyl, C1 -C4-alkoxy or halogen;
R3 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen, OH, -O-C1-C4-alkylene-COOH or -O-C1-C4-alkylene-COO-C1-C4-alkyl;
R4 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
X- denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
R2 denotes hydrogen, C1-C4-alkyl, C1 -C4-alkoxy or halogen;
R3 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen, OH, -O-C1-C4-alkylene-COOH or -O-C1-C4-alkylene-COO-C1-C4-alkyl;
R4 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy or halogen;
X- denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
2) Enantiomerically pure compounds of general formula 1 according to C1aim 1, wherein R1 denotes hydrogen or halogen;
R2 denotes hydrogen or halogen;
R3 denotes hydrogen, C1-C4-alkoxy or halogen;
R4 denotes hydrogen or halogen;
X- denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
R2 denotes hydrogen or halogen;
R3 denotes hydrogen, C1-C4-alkoxy or halogen;
R4 denotes hydrogen or halogen;
X- denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
3) Enantiomerically pure compounds of general formula 1 according to claim 1 or 2, wherein R1 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
R2 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
R3 denotes hydrogen, methoxy, ethoxy, fluorine or chlorine, preferably hydrogen, methoxy, ethoxy or fluorine;
R4 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
X- denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
R2 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
R3 denotes hydrogen, methoxy, ethoxy, fluorine or chlorine, preferably hydrogen, methoxy, ethoxy or fluorine;
R4 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
X- denotes an anion with a single negative charge, preferably an anion with a single negative charge selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
4) Enantiomerically pure compounds of general formula 1 according to one of claims 1 to 3, wherein R1 denotes hydrogen or fluorine;
R2 denotes hydrogen;
R3 denotes methoxy, ethoxy or fluorine;
R4 denotes hydrogen;
X- denotes an anion with a single negative charge selected from among chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate and succinate;
optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
R2 denotes hydrogen;
R3 denotes methoxy, ethoxy or fluorine;
R4 denotes hydrogen;
X- denotes an anion with a single negative charge selected from among chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate and succinate;
optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
5) Enantiomerically pure compounds of general formula 1 according to one of claims 1 to 3, wherein R1 denotes hydrogen;
R2 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
R3 denotes hydrogen;
R4 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
X- denotes an anion with a single negative charge selected from among chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate and succinate;
optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
R2 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
R3 denotes hydrogen;
R4 denotes hydrogen, fluorine or chlorine, preferably hydrogen or fluorine;
X- denotes an anion with a single negative charge selected from among chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate and succinate;
optionally in the form of the tautomers, mixtures of the tautomers, hydrates or solvates thereof.
6) Enantiomerically pure compounds of general formula 1 according to one of claims 1 to 5, characterised in that they are in crystalline form, optionally in the form of their crystalline tautomers, crystalline hydrates or crystalline solvates.
7) Enantiomerically pure compounds of general formula 1 according to one of claims 1 to 6 as pharmaceutical compositions.
8) Use of enantiomerically pure compounds of general formula 1 according to one of claims 1 to 6 for preparing a pharmaceutical composition for the treatment of respiratory complaints.
9) Pharmaceutical formulation, characterised in that it contains a compound of formula 1 according to one of claims 1 to 6.
10) Compounds of formula 5 wherein OPG denotes a hydroxyl function protected by a protective group PG, preferably a group which is selected from -O-C1-C4-alkyl, -O-benzyl and -O-CO-C1-C4-alkyl.
11) Use of a compound of formula 5 according to claim 10 as a starting compound for preparing a compound of formula 1 according to one of claims 1 to 6.
12) Compounds of formula 7 wherein OPG denotes a hydroxyl function protected by a protective group PG, preferably a group which is selected from -O-C1-C4-alkyl, -O-benzyl and -O-CO-C1-C4-alkyl, and wherein the groups R1, R2, R3 and R4 may have the meanings given in claims 1 to 5
13) Use of a compound of formula 7 according to claim 12 as a starting compound for preparing a compound of formula 1 according to one of claims 1 to 6.
14) Compounds of formula 1' wherein the groups R1, R2, R3 and R4 may have the meanings given in claims 1 to 5.
15) Use of a compound of formula 1' according to claim 14 as a starting compound for preparing a compound of formula 1 according to one of claims 1 to 6.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004024454A DE102004024454A1 (en) | 2004-05-14 | 2004-05-14 | Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals |
DE102004024454.5 | 2004-05-14 | ||
PCT/EP2005/005079 WO2005111005A1 (en) | 2004-05-14 | 2005-05-11 | Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2562859A1 true CA2562859A1 (en) | 2005-11-24 |
CA2562859C CA2562859C (en) | 2012-05-08 |
Family
ID=34966720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2562859A Active CA2562859C (en) | 2004-05-14 | 2005-05-11 | Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1789405B1 (en) |
JP (1) | JP2007537196A (en) |
KR (1) | KR101270447B1 (en) |
CN (4) | CN106146425A (en) |
AU (1) | AU2005243469B2 (en) |
BR (1) | BRPI0511102B1 (en) |
CA (1) | CA2562859C (en) |
CY (1) | CY1114702T1 (en) |
DE (1) | DE102004024454A1 (en) |
DK (1) | DK1789405T3 (en) |
ES (1) | ES2431118T3 (en) |
IL (1) | IL179217A (en) |
MX (1) | MXPA06013218A (en) |
NZ (1) | NZ551416A (en) |
PL (1) | PL1789405T3 (en) |
PT (1) | PT1789405E (en) |
RU (1) | RU2378262C2 (en) |
SI (1) | SI1789405T1 (en) |
WO (1) | WO2005111005A1 (en) |
ZA (1) | ZA200607152B (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7423036B2 (en) | 2005-02-19 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Long-acting betamimetics for the treatment of respiratory complaints |
US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
US7491719B2 (en) | 2004-05-14 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
US7534789B2 (en) | 2006-03-15 | 2009-05-19 | Boehringer Ingelheim International Gmbh | Enantiomeric pure β agonists, manufacturing and use as a medicament thereof |
US7709474B2 (en) | 2006-08-22 | 2010-05-04 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, manufacturing and use thereof |
US7727984B2 (en) | 2002-11-15 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US8106060B2 (en) | 2005-07-30 | 2012-01-31 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8119648B2 (en) | 2002-08-21 | 2012-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US8394791B2 (en) | 2008-02-22 | 2013-03-12 | Boehringer Ingelheim International Gmbh | Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug |
US8420809B2 (en) | 2005-08-15 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of betamimetics |
AU2008208813B2 (en) * | 2007-01-25 | 2013-05-09 | Boehringer Ingelheim International Gmbh | Method for producing betamimetics |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US8697868B2 (en) | 2004-02-18 | 2014-04-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9266888B2 (en) | 2006-05-04 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004024452A1 (en) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol formulation for the inhalation of beta agonists |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
RU2442771C2 (en) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Derivants of bicyclo[2, 2, 1] hept-7-ylamine and their applications |
EP1986644A1 (en) * | 2006-02-16 | 2008-11-05 | Boehringer Ingelheim International GmbH | Drug combinations for the treatment of respiratory tract diseases |
UY30542A1 (en) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | AEROSOL FORMULATION FOR INHALATION OF BETA AGONISTS |
WO2009059893A1 (en) * | 2007-11-05 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Crystalline hydrate of betamimetika and use as medicament thereof |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
SI2379507T1 (en) | 2008-12-30 | 2014-02-28 | Pulmagen Therapeutics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
WO2012022796A2 (en) * | 2010-08-20 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Novel combinations |
EP2906218B1 (en) | 2012-10-09 | 2016-12-14 | Boehringer Ingelheim International GmbH | Beta-2-adrenoceptor agonist for the treatment of cough |
CN102993116A (en) * | 2012-12-04 | 2013-03-27 | 常州大学 | Preparation method of benzoxazine excitant |
SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
JP2019536812A (en) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nintedanib for use in methods of treating interstitial lung disease by co-administration with olodaterol |
ES2900283T3 (en) | 2016-12-20 | 2022-03-16 | Inke Sa | Improved process for the manufacture of (R)-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3 hydrochloride (4H)-one |
CN109096218B (en) * | 2018-08-06 | 2020-10-27 | 上海方予健康医药科技有限公司 | Oxydterol hydrochloride crystal form A and preparation method thereof |
CN108822054B (en) * | 2018-08-06 | 2021-06-22 | 上海方予健康医药科技有限公司 | Oxydterol hydrochloride crystal form C and preparation method thereof |
CN108997248B (en) * | 2018-08-06 | 2023-08-01 | 上海方予健康医药科技有限公司 | Crystal form B of ondarot hydrochloride and preparation method thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656168A (en) * | 1980-12-23 | 1987-04-07 | Merck & Co., Inc. | (3-aralkylamino-2-or-propoxy)heterocyclic compounds in method of effecting bronchodilation |
DE3134590A1 (en) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | NEW BENZO HETEROCYCLES |
US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
DE3743265A1 (en) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | NEW AMMONIUM COMPOUNDS, THEIR MANUFACTURE AND USE |
US5502078A (en) * | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
JPH0912518A (en) * | 1995-06-26 | 1997-01-14 | Kanegafuchi Chem Ind Co Ltd | Production of 2-(1-(3'4'-dimethoxyphenlyl)-2-propyamino)-1-(3'-chloropheml)-ethanol |
JPH11255743A (en) * | 1998-03-06 | 1999-09-21 | Dainippon Pharmaceut Co Ltd | Production of optically active indole derivative and intermediate for producing the same |
DZ3478A1 (en) | 2000-10-12 | 2002-04-18 | Boehringer Ingelheim Pharma | CRYSTALLINE MONOHYDRATE, PROCESS FOR ITS MANUFACTURE AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT. |
HUP0401073A2 (en) * | 2000-12-21 | 2004-09-28 | Aventis Pharma Deutschland Gmbh. | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
ME00412B (en) | 2001-06-22 | 2011-10-10 | Boehringer Ingelheim Pharma | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
DE10253282A1 (en) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration |
EP1789394A1 (en) * | 2004-05-13 | 2007-05-30 | Boehringer Ingelheim International Gmbh | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
-
2004
- 2004-05-14 DE DE102004024454A patent/DE102004024454A1/en not_active Withdrawn
-
2005
- 2005-05-11 CN CN201610262144.3A patent/CN106146425A/en active Pending
- 2005-05-11 CN CN201610884642.1A patent/CN106995414A/en active Pending
- 2005-05-11 SI SI200531756T patent/SI1789405T1/en unknown
- 2005-05-11 JP JP2007512081A patent/JP2007537196A/en active Pending
- 2005-05-11 CN CNA2005800154333A patent/CN101133039A/en active Pending
- 2005-05-11 AU AU2005243469A patent/AU2005243469B2/en active Active
- 2005-05-11 RU RU2006144123/04A patent/RU2378262C2/en active Protection Beyond IP Right Term
- 2005-05-11 BR BRPI0511102-1A patent/BRPI0511102B1/en active IP Right Grant
- 2005-05-11 PL PL05737938T patent/PL1789405T3/en unknown
- 2005-05-11 NZ NZ551416A patent/NZ551416A/en unknown
- 2005-05-11 CN CN201210347732.9A patent/CN102827097B/en active Active
- 2005-05-11 WO PCT/EP2005/005079 patent/WO2005111005A1/en active Application Filing
- 2005-05-11 CA CA2562859A patent/CA2562859C/en active Active
- 2005-05-11 EP EP05737938.0A patent/EP1789405B1/en active Active
- 2005-05-11 DK DK05737938.0T patent/DK1789405T3/en active
- 2005-05-11 KR KR1020067026273A patent/KR101270447B1/en active IP Right Grant
- 2005-05-11 MX MXPA06013218A patent/MXPA06013218A/en not_active Application Discontinuation
- 2005-05-11 PT PT57379380T patent/PT1789405E/en unknown
- 2005-05-11 ES ES05737938T patent/ES2431118T3/en active Active
-
2006
- 2006-08-28 ZA ZA200607152A patent/ZA200607152B/en unknown
- 2006-11-13 IL IL179217A patent/IL179217A/en active IP Right Grant
-
2013
- 2013-09-18 CY CY20131100810T patent/CY1114702T1/en unknown
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119648B2 (en) | 2002-08-21 | 2012-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US9108964B2 (en) | 2002-08-21 | 2015-08-18 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8664232B2 (en) | 2002-08-21 | 2014-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8178541B2 (en) | 2002-08-21 | 2012-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7727984B2 (en) | 2002-11-15 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US7786111B2 (en) | 2002-11-15 | 2010-08-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US8044046B2 (en) | 2002-11-15 | 2011-10-25 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US8697868B2 (en) | 2004-02-18 | 2014-04-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US8034809B2 (en) | 2004-05-14 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
US7491719B2 (en) | 2004-05-14 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
US8541450B2 (en) | 2004-11-05 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US9499546B2 (en) | 2004-11-05 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US8883805B2 (en) | 2004-11-05 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US7423036B2 (en) | 2005-02-19 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Long-acting betamimetics for the treatment of respiratory complaints |
US8106060B2 (en) | 2005-07-30 | 2012-01-31 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8637530B2 (en) | 2005-07-30 | 2014-01-28 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8420809B2 (en) | 2005-08-15 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of betamimetics |
US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
US7939658B2 (en) | 2006-03-15 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof |
US7534789B2 (en) | 2006-03-15 | 2009-05-19 | Boehringer Ingelheim International Gmbh | Enantiomeric pure β agonists, manufacturing and use as a medicament thereof |
US8673927B2 (en) | 2006-05-04 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US9815837B2 (en) | 2006-05-04 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9173859B2 (en) | 2006-05-04 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9266888B2 (en) | 2006-05-04 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Polymorphs |
US7709474B2 (en) | 2006-08-22 | 2010-05-04 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, manufacturing and use thereof |
AU2008208813B2 (en) * | 2007-01-25 | 2013-05-09 | Boehringer Ingelheim International Gmbh | Method for producing betamimetics |
US8394791B2 (en) | 2008-02-22 | 2013-03-12 | Boehringer Ingelheim International Gmbh | Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug |
US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
US9212183B2 (en) | 2008-12-23 | 2015-12-15 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9199998B2 (en) | 2011-07-15 | 2015-12-01 | Boehringer Ingelheim Internatioal Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Also Published As
Publication number | Publication date |
---|---|
DE102004024454A1 (en) | 2005-12-08 |
PT1789405E (en) | 2013-08-22 |
EP1789405A1 (en) | 2007-05-30 |
CN106146425A (en) | 2016-11-23 |
MXPA06013218A (en) | 2007-02-08 |
KR20070011602A (en) | 2007-01-24 |
RU2378262C2 (en) | 2010-01-10 |
DK1789405T3 (en) | 2013-10-14 |
CN102827097B (en) | 2016-11-23 |
IL179217A (en) | 2012-08-30 |
AU2005243469B2 (en) | 2011-09-29 |
WO2005111005A1 (en) | 2005-11-24 |
IL179217A0 (en) | 2007-03-08 |
AU2005243469A1 (en) | 2005-11-24 |
CN101133039A (en) | 2008-02-27 |
JP2007537196A (en) | 2007-12-20 |
RU2006144123A (en) | 2008-09-10 |
CA2562859C (en) | 2012-05-08 |
NZ551416A (en) | 2011-04-29 |
PL1789405T3 (en) | 2013-12-31 |
ZA200607152B (en) | 2008-04-30 |
EP1789405B1 (en) | 2013-07-17 |
CY1114702T1 (en) | 2016-10-05 |
CN102827097A (en) | 2012-12-19 |
SI1789405T1 (en) | 2013-09-30 |
CN106995414A (en) | 2017-08-01 |
KR101270447B1 (en) | 2013-06-04 |
BRPI0511102B1 (en) | 2021-05-25 |
ES2431118T3 (en) | 2013-11-25 |
BRPI0511102A (en) | 2007-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2562859A1 (en) | Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug | |
ES2947446T3 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
CA2506082A1 (en) | Novel medicaments for the treatment of chronic obstructive pulmonary disease | |
WO2020065453A1 (en) | Process of manufacture of a compound for inhibiting the activity of shp2 | |
JP2009506014A5 (en) | ||
SA519402422B1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
CA2471593A1 (en) | 2-heteroarylcarboxamides | |
TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
CA2632194A1 (en) | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
JP2006182786A5 (en) | ||
CN1893948A (en) | Muscarinic acetylcholine receptor antagonists | |
CA2782521A1 (en) | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride | |
RU2013151803A (en) | BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN THERAPY | |
TW201121960A (en) | Chromenone derivatives | |
CA2436659A1 (en) | Cannabinoid receptor ligands | |
JP2010532387A5 (en) | ||
JP2012522814A5 (en) | ||
CA2471578A1 (en) | Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments | |
JP2014511898A5 (en) | ||
WO2000056728A1 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
WO2007002764A3 (en) | Di-substituted oxadiazoles as cxc-chemokine receptor ligands | |
AR064134A1 (en) | DERIVATIVES OF 2-AMINOQUINOLINE, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE ANTAGONISM OF 5-HT5A RECEPTORS. | |
CA3157404A1 (en) | Novel salt of terphenyl compound | |
JP2004507527A5 (en) | ||
EP3327012A1 (en) | Crystalline forms of bilastine and preparation methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |